Integrating electronic health record genotype and phenotype datasets to transform patient care

Clinical Pharmacology and Therapeutics

Volumn 99, Issue 3, 2016, Pages 298-305

  Roden, D M ^a,b   Denny, J C ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; SIMVASTATIN;

ARTICLE; DRUG DEVELOPMENT; DRUG REPOSITIONING; DRUG RESPONSE; ELECTRONIC MEDICAL RECORD; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEALTH; HEALTH CARE SYSTEM; HEMOCHROMATOSIS; HUMAN; MEDICAL INFORMATICS; MEDICINE; PATIENT CARE; PENETRANCE; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; ELECTRONIC HEALTH RECORD; FACTUAL DATABASE; HEALTH CARE DELIVERY; PROCEDURES;

DATABASES, FACTUAL; DELIVERY OF HEALTH CARE; ELECTRONIC HEALTH RECORDS; GENOTYPE; HUMANS; PHENOTYPE; PRECISION MEDICINE;

EID: 84958846533     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.321     Document Type: Article

References (73)

1. Collins F.S., & Varmus H. A new initiative on precision medicine. N. Engl. J. Med. 372, 793-795 (2015
2. Adler N.E., & Stead W.W. Patients in context-EHR capture of social, and behavioral determinants of health. N. Engl. J. Med. 372, 698-701 (2015
3. Gottesman O., et al. The Electronic Medical Records, and Genomics (eMERGE). Network: past, present, and future. Genet. Med. 15, 761-771 (2013
4. Gaziano J.M., et al. Million Veteran Program: A mega-biobank to study genetic influences on health, and disease. J. Clin. Epidemiol. (2015); e-pub ahead of print
5. Banda Y., et al. Characterizing race/ethnicity, and genetic ancestry for 100,000 subjects in the Genetic Epidemiology Research on Adult Health, and Aging (GERA). Cohort. Genetics 200, 1285-1295 (2015
6. Allen N.E., Sudlow C., Peakman T., Collins R., & Biobank O.B.O.U. UK Biobank Data: come, and get it. Sci. Transl. Med. 6, 224ed4 (2014
7. Gulcher J.R., & Stefansson K. The Icelandic Healthcare Database, and informed consent. N. Engl. J. Med. 342, 1827-1830 (2000
8. Bowton E., et al. Biobanks, and electronic medical records: enabling cost-effective research. Sci. Transl. Med. 6, 234cm3 (2014
9. The Wellcome Trust Case Control C. Genome-wide association study of 14,000 cases of seven common diseases, and 3,000 shared controls. Nature 447, 661-678 (2007
10. Denny J.C., et al. Variants near FOXE1 are associated with hypothyroidism, and other thyroid conditions: using electronic medical records for genome-and phenome-wide studies. Am. J. Hum. Genet. 89, 529-542 (2011
11. Wei W.Q., Teixeira P.L., Mo H., Cronin R.M., Warner J.L., & Denny J.C. Combining billing codes, clinical notes, and medications from electronic health records provides superior phenotyping performance. J. Am. Med. Inform. Assoc. (2015); e-pub ahead of print
12. Wei W.Q., & Denny J.C. Extracting research-quality phenotypes from electronic health records to support precision medicine. Genome Med. 7, 41 (2015
13. Ritchie M.D., et al. Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. Am. J. Hum. Genet. 86, 560-572 (2010
14. Lin C., et al. Automatic identification of methotrexate-induced liver toxicity in patients with rheumatoid arthritis from the electronic medical record. J. Am. Med. Inform. Assoc. 22, e151-e161 (2015
15. Carroll R.J., et al. Portability of an algorithm to identify rheumatoid arthritis in electronic health records. J. Am. Med. Inform. Assoc. 19, e162-e169 (2012
16. Kho A.N., et al. Use of diverse electronic medical record systems to identify genetic risk for type 2 diabetes within a genome-wide association study. J. Am. Med. Inform. Assoc. 19, 212-218 (2011
17. Mo H., et al. Desiderata for computable representations of electronic health records-driven phenotype algorithms. J. Am. Med. Inform. Assoc. 22, 1220-1230 (2015
18. Murphy S.N., Mendis M.E., Berkowitz D.A., Kohane I., & Chueh H.C. Integration of clinical, and genetic data in the i2b2 architecture. AMIA Annu. Symp. Proc., 1040 (2006
19. Ding K., et al. Genetic variants that confer resistance to malaria are associated with red blood cell traits in African-Americans: an electronic medical record-based genome-wide association study. G3 (Bethesda, MD). 3, 1061-1068 (2013
20. Crosslin D.R., et al. Genetic variation in the HLA region is associated with susceptibility to herpes zoster. Genes Immun. 16, 1-7 (2015
21. Shameer K., et al. A genome-and phenome-wide association study to identify genetic variants influencing platelet count, and volume, and their pleiotropic effects. Hum. Genet. 133, 95-109 (2014
22. Kullo I.J., Ding K., Jouni H., Smith C.Y., & Chute C.G. A genomewide association study of red blood cell traits using the electronic medical record. PLoS One 5, (2010
23. Delaney J.T., et al. Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin. Pharmacol. Ther. 91, 257-263 (2012
24. Ramirez A.H., et al. Predicting warfarin dosages in European-American, and African-American subjects using DNA samples linked to an electronic health record. Pharmagenomics (2012); e-pub ahead of print
25. Birdwell K.A., et al. The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. Pharmacogenet. Genomics 22, 32-42 (2012
26. Onitilo A.A., et al. Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. Breast Cancer Res. Treat. 115, 643-650 (2009
27. Onitilo A.A., et al. Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. Breast Cancer Res. Treat. 115, 643-650 (2009
28. Karnes J.H., et al. A genome-wide association study of heparininduced thrombocytopenia using an electronic medical record. Thrombosis Haemostasis 113, 772-681 (2015
29. Van Driest S.L., et al. Genome-Wide Association Study of Serum Creatinine Levels during Vancomycin Therapy. PLoS One 10, e0127791 (2015
30. Karol S.E., et al. Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. Blood 126, 1770-1776 (2015
31. Wells Q.S., et al. Genomewide-association identifies a novel locus for anthracycline cardiotoxicity. Circulation 128, A15509 (2013
32. Kawai V.K., et al. Genotype, and risk of major bleeding during warfarin treatment. Pharmacogenomics 15, 1973-1983 (2014
33. Roth J.A., et al. Genetic risk factors for major bleeding in warfarin patients in a community setting. Clin. Pharmacol. Ther. 95, 636-643 (2014
34. Kimmel S.E., et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N. Engl. J. Med. 369, 2283-2293 (2013
35. Pirmohamed M., et al. A randomized trial of genotype-guided dosing of warfarin. N. Engl. J. Med. 369, 2294-2303 (2013
36. Perera M.A., Cavallari L.H., & Johnson J.A. Warfarin pharmacogenetics: an illustration of the importance of studies in minority populations. Clin. Pharmacol. Ther. 95, 242-244 (2014
37. Perera M.A., et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet 382, 790-796 (2013
38. Limdi N.A., et al. Race influences warfarin dose changes associated with genetic factors. Blood 126, 539-545 (2015
39. Ritchie M.D., et al. Genome-and phenome-wide analyses of cardiac conduction identifies markers of arrhythmia risk. Circulation 127, 1377-1385 (2013
40. Denny J.C., et al. PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics 26, 1205-1210 (2010
41. Denny J.C., et al. Systematic comparison of phenome-wide association study of electronic medical record data, and genome-wide association study data. Nat. Biotechnol. 31, 1102-1111 (2013
42. Hebbring S.J., Schrodi S.J., Ye Z., Zhou Z., Page D., & Brilliant M.H. A PheWAS approach in studying HLA-DRB1∗1501. Genes Immun. 14, 187-191 (2013
43. Rastegar-Mojarad M., Ye Z., Kolesar J.M., Hebbring S.J., & Lin S.M. Opportunities for drug repositioning from phenome-wide association studies. Nat. Biotechnol. 33, 342-345 (2015
44. Hall M.A., et al. Detection of pleiotropy through a phenome-wide association study (PheWAS). of epidemiologic data as part of the Environmental Architecture for Genes Linked to Environment (EAGLE). study. PLoS Genet. 10, e1004678 (2014
45. Finucane H.K., et al. Partitioning heritability by functional annotation using genome-wide association summary statistics. Nat. Genet. 47, 1228-1235 (2015
46. Li L., et al. Identification of type 2 diabetes subgroups through topological analysis of patient similarity. Sci. Transl. Med. 7, 311ra174-311ra174 (2015
47. Xu H., et al. Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality. J. Am. Med. Inform. Assoc. (2014); e-pub ahead of print
48. Okada Y., et al. Genetics of rheumatoid arthritis contributes to biology, and drug discovery. Nature 506, 376-381 (2014
49. Cohen J.C., Boerwinkle E., Mosley T.H., Jr., & Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264-1272 (2006
50. Desai N.R., & Sabatine M.S. PCSK9 inhibition in patients with hypercholesterolemia. Trends Cardiovasc. Med. 25, 567-574 (2015
51. Stitziel N.O., et al. Inactivating mutations in NPC1L1, and protection from coronary heart disease. N. Engl. J. Med. 371, 2072-2082 (2014
52. Collins F. Opportunities, and challenges for the NIH-an interview with Francis Collins. Interview by Robert Steinbrook. N. Engl. J. Med. 361, 1321-1323 (2009
53. Shuldiner A.R., et al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin. Pharmacol. Ther. 94, 207-210 (2013
54. Manolio T.A., et al. Implementing genomic medicine in the clinic: the future is here. Genet. Med. 15, 258-267 (2013
55. Stimpfle F., et al. Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome, and early dual antiplatelet therapy in the emergency setting. Thromb. Res. 134, 105-110 (2014
56. Weitzel K.W., et al. Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am. J. Med. Genet. C Semin. Med. Genet. 166C, 56-67 (2014
57. Pulley J.M., et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT Project. Clin. Pharmacol. Ther. 92, 87-95 (2012
58. Bell G.C., et al. Development, and use of active clinical decision support for preemptive pharmacogenomics. J. Am. Med. Inform. Assoc. 21, e93-99 (2014
59. Schildcrout J.S., et al. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin. Pharmacol. Ther. 92, 235-2342 (2012
60. Van Driest S.L., et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clin. Pharmacol. Ther. 95, 423-431 (2014
61. Relling M.V., & Klein T.E. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther. 89, 464-467 (2011
62. Hulot J.S., et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108, 2244-2247 (2006
63. Mega J.L., et al. Reduced-function CYP2C19 genotype, and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304, 1821-1830 (2010
64. Cavallari L.H., et al. Abstract 11802: clinical implementation of CYP2C19-genotype guided antiplatelet therapy reduces cardiovascular events after PCI. Circulation 132, A11802 (2015
65. Mallal S., et al. HLA-B∗5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358, 568-579 (2008
66. Rehm H.L., et al. ClinGen-the clinical genome resource. N. Engl. J. Med. 372, 2235-2242 (2015
67. Gallego, Carlos J., et al. Penetrance of hemochromatosis in HFE genotypes resulting in p.Cys282Tyr, and p.[Cys282Tyr]; [His63Asp] in the eMERGE Network. Am. J. Hum. Genet. 97, 512-520 (2015
68. Van Driest S., et al. Rare potentially pathogenic variants in the congenital arrhythmia syndrome disease genes SCN5A, and KCNH2 are detected frequently but rarely associated with arrhythmia phenotypes in electronic health records. Accepted for presentation, Am. Soc. Hum. Genet. 2014 Scientific Sessions (2014
69. https://www.nih.gov/sites/default/files/research-training/initiatives/pmi/pmi-working-group-report-20150917-2.pdf (2015). Accessed 23 November, 2015
70. Wei W.Q., et al. Characterization of statin dose response in electronic medical records. Clin. Pharmacol. Ther. 95, 331-338 (2014
71. McGeachie M.J., et al. CTNNA3, and SEMA3D: promising loci for asthma exacerbation identified through multiple genome-wide association studies. J. Allergy Clin. Immunol. (2015); e-pub ahead of print
72. Naidoo D., et al. A polymorphism in HLA-G modifies statin benefit in asthma. Pharmacogenom. J. 15, 272-277 (2015
73. Hoh B.L., et al. CYP2C19, and CES1 polymorphisms, and efficacy of clopidogrel, and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease. J. Neurosurg. 1-6 (2015